ProMIS Neurosciences Files 8-K on Board Changes and Votes

Ticker: PMN · Form: 8-K · Filed: 2025-06-13T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, board-changes, shareholder-vote

TL;DR

ProMIS Neurosciences is changing its board and officers, and holding shareholder votes. Big governance shakeup.

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on June 13, 2025, reporting on events from June 12, 2025. The filing covers the departure and election of directors, appointment of officers, executive compensation arrangements, and submission of matters to a vote of security holders. It also includes financial statements and exhibits.

Why It Matters

This filing indicates significant corporate governance changes and potential shareholder votes, which could impact the company's strategic direction and leadership.

Risk Assessment

Risk Level: medium — Changes in board composition and executive appointments can signal strategic shifts or internal challenges that may affect future performance.

Key Players & Entities

FAQ

What specific director departures and elections are detailed in the filing?

The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of report, but specific names are not provided in this excerpt.

Are there any changes to executive compensation arrangements?

Yes, the filing lists "Compensatory Arrangements of Certain Officers" as an item of report, suggesting potential updates or disclosures regarding executive pay.

What matters were submitted to a vote of security holders?

The filing explicitly states "Submission of Matters to a Vote of Security Holders" as an item of report, indicating that shareholder votes were conducted or are being reported on.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st, as indicated by "FISCAL YEAR END: 1231".

Where is ProMIS Neurosciences Inc. headquartered?

ProMIS Neurosciences Inc. is headquartered in Toronto, Ontario, Canada, with its business address listed as Suite 200, 1920 Yonge Street, Toronto, Ontario.

From the Filing

0001558370-25-008600.txt : 20250613 0001558370-25-008600.hdr.sgml : 20250613 20250613080020 ACCESSION NUMBER: 0001558370-25-008600 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250612 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 251044768 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 pmn-20250612x8k.htm 8-K PROMIS NEUROSCIENCES INC._June 12, 2025 0001374339 false 0001374339 2025-06-12 2025-06-12 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) ​ Ontario, Canada      001-41429      98-0647155 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) ​ ​ Suite 200 , 1920 Yonge Street , Toronto , Ontario             M4S 3E2 (Address of principal executive offices)       (Zip Code) ​ Registrant’s telephone number, including area code: ( 416 ) 847-6898 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class      Trading Symbol(s)      Name of Each Exchange on Which Registered Common Shares, no par value per share ​ PMN The Nasdaq Capital Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company   ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As further described in Item 5.07 below, the stockholders of ProMIS Neurosciences Inc

View on Read The Filing